PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK,...

PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...

PAVmed to Hold Business Update Conference Call on September 5, 2019 NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...

PAVmed Provides Business Update  FDA confirms receipt of CarpX 510(k) resubmission for review NEW YORK, July 25, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...